Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorRAFII, Hanadi
dc.contributor.authorRUGGERI, Annalisa
dc.contributor.authorKENZEY, Chantal
dc.contributor.authorSANZ, Jaime
dc.contributor.authorTOUR, Regis Peffault De la
dc.contributor.authorESQUIROL, Albert
dc.contributor.authorMICHEL, Gerard
dc.contributor.authorCHEVALLIER, Patrice
dc.contributor.authorRUBIO, Marie-Therese
dc.contributor.authorCORNELISSEN, Jan J.
dc.contributor.authorMICHALLET, Mauricette
dc.contributor.authorVOLT, Fernanda
dc.contributor.authorRIVERA-FRANCO, Monica M.
dc.contributor.authorSCIGLIUOLO, Graziana Maria
dc.contributor.authorCAPPELLI, Barbara
dc.contributor.authorROCHA, Vanderson
dc.contributor.authorGLUCKMAN, Eliane
dc.date.accessioned2023-08-16T17:45:42Z
dc.date.available2023-08-16T17:45:42Z
dc.date.issued2023
dc.description.abstractSubsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. SNs developed in 233 patients and 84 were of pediatric age. Indications for UCBT were malignant hematological diseases in 199 patients (85%). Three groups of SNs were observed. Posttransplant lymphoproliferative disorders (PTLD) were reported in 145 patients in a median of 4 months after UCBT. Of these, 9 patients died from relapse, 83 from PTLD, and 24 from transplant-related causes. At last follow-up, 29 were alive; 5-year overall survival (OS) after PTLD diagnosis was 21%. Acute leukemia/myelodysplasia (AL/MDS) was diagnosed in 23 patients in a median of 28 months after UCBT and included 3 donor-cell AL. Four of 23 patients died from relapse of primary disease, 8 from progression of SNs, and 4 from TRM. Seven patients remain alive; the 5-year OS after AL/MDS diagnosis was 36%. Solid tumors (ST) were reported in 65 patients in a median of 54 months after UCBT. Most common tumor sites were lung, thyroid, bone, and soft tissue. A total of 33 patients died (26 owing to ST, 6 to relapse of primary disease, and 1 cause missing). At last follow-up, 32 of 65 patients were alive; the 5-year OS after the diagnosis of ST was 51%. In conclusion, despite their poor outcomes, SNs that occur after UCBT are extremely rare. Identification of risk factors and early detection may help to improve OS.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationBLOOD ADVANCES, v.7, n.10, p.1976-1986, 2023
dc.identifier.doi10.1182/bloodadvances.2022007941
dc.identifier.eissn2473-9537
dc.identifier.issn2473-9529
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/54596
dc.language.isoeng
dc.publisherELSEVIEReng
dc.relation.ispartofBlood Advances
dc.rightsopenAccesseng
dc.rights.holderCopyright ELSEVIEReng
dc.subject.otherstem-cell transplantationeng
dc.subject.otheracute myeloid-leukemiaeng
dc.subject.otherposttransplant lymphoproliferative disordereng
dc.subject.other2nd solid cancerseng
dc.subject.otherebv reactivationeng
dc.subject.otherrisk-factorseng
dc.subject.othermarrow-transplantationeng
dc.subject.otherbone-marroweng
dc.subject.otherhematologic malignancieseng
dc.subject.othermyelodysplastic syndromeeng
dc.subject.wosHematologyeng
dc.titleOutcomes of subsequent neoplasms after umbilical cord blood transplantation in Europeeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryMônaco
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryisomc
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisonl
hcfmusp.author.externalRAFII, Hanadi:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalRUGGERI, Annalisa:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; IRCCS San Raffaele Sci Inst, Haematol & Bone Marrow Transplant Unit, Milan, Italy
hcfmusp.author.externalKENZEY, Chantal:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalSANZ, Jaime:Hosp Univ La Fe, Dept Hematol, Valencia, Spain
hcfmusp.author.externalTOUR, Regis Peffault De la:St Louis Hosp, AP HP, Bone Marrow Transplant Unit, Paris, France
hcfmusp.author.externalESQUIROL, Albert:Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau, Hematol Dept, Barcelona, Spain; Univ Autonoma Barcelona, Jose Carreras Leukemia Res Inst, Barcelona, Spain
hcfmusp.author.externalMICHEL, Gerard:Hop Pediat Timone, Dept Hematol, Marseille, France
hcfmusp.author.externalCHEVALLIER, Patrice:Hosp Hotel Dieu, Dept Hematol, Nantes, France
hcfmusp.author.externalRUBIO, Marie-Therese:CHRU Nancy, Dept Hematol, Nancy, France
hcfmusp.author.externalCORNELISSEN, Jan J.:Erasmus MC, Dept Hematol, Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands
hcfmusp.author.externalMICHALLET, Mauricette:Ctr Leon Berard, Dept Hematol & Oncol, Lyon, France
hcfmusp.author.externalVOLT, Fernanda:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalRIVERA-FRANCO, Monica M.:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalSCIGLIUOLO, Graziana Maria:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalCAPPELLI, Barbara:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.author.externalGLUCKMAN, Eliane:Univ Paris Cite, Hop St Louis, AP HP, Eurocord,Inst Rech St Louis IRSL EA3518, Paris, France; Monacord, Ctr Sci Monaco, Monaco, Monaco
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcVANDERSON GERALDO ROCHA
hcfmusp.description.beginpage1976
hcfmusp.description.endpage1986
hcfmusp.description.issue10
hcfmusp.description.volume7
hcfmusp.origemWOS
hcfmusp.origem.pubmed36350759
hcfmusp.origem.scopus2-s2.0-85163528107
hcfmusp.origem.wosWOS:001004368700001
hcfmusp.publisher.cityAMSTERDAMeng
hcfmusp.publisher.countryNETHERLANDSeng
hcfmusp.relation.referenceAbbas Fedaey, 2020, World J Transplant, V10, P29, DOI 10.5500/wjt.v10.i2.29eng
hcfmusp.relation.referenceAkhtari M, 2013, CANCER BIOL THER, V14, P1077, DOI 10.4161/cbt.26342eng
hcfmusp.relation.referenceAndo T, 2006, LEUKEMIA, V20, P744, DOI 10.1038/sj.leu.2404121eng
hcfmusp.relation.referenceArmand P, 2007, BIOL BLOOD MARROW TR, V13, P505, DOI 10.1016/j.bbmt.2007.02.005eng
hcfmusp.relation.referenceAtsuta Y, 2014, ANN ONCOL, V25, P435, DOI 10.1093/annonc/mdt558eng
hcfmusp.relation.referenceBaker KS, 2003, J CLIN ONCOL, V21, P1352, DOI 10.1200/JCO.2003.05.108eng
hcfmusp.relation.referenceBallen KK, 2007, BIOL BLOOD MARROW TR, V13, P82, DOI 10.1016/j.bbmt.2006.08.041eng
hcfmusp.relation.referenceBallen KK, 2010, BIOL BLOOD MARROW TR, V16, P1025, DOI 10.1016/j.bbmt.2010.02.014eng
hcfmusp.relation.referenceBhatia S, 2011, EXPERT REV HEMATOL, V4, P437, DOI [10.1586/ehm.11.39, 10.1586/EHM.11.39]eng
hcfmusp.relation.referenceBlaes AH, 2010, BIOL BLOOD MARROW TR, V16, P287, DOI 10.1016/j.bbmt.2009.10.008eng
hcfmusp.relation.referenceBrunstein CG, 2002, BONE MARROW TRANSPL, V29, P999, DOI 10.1038/sj.bmt.1703577eng
hcfmusp.relation.referenceBrunstein CG, 2007, BLOOD, V110, P3064, DOI 10.1182/blood-2007-04-067215eng
hcfmusp.relation.referenceBrunstein CG, 2006, BLOOD, V108, P2874, DOI 10.1182/blood-2006-03-011791eng
hcfmusp.relation.referenceCurtis RE, 1999, BLOOD, V94, P2208eng
hcfmusp.relation.referenceCutting RJ, 2008, BONE MARROW TRANSPL, V42, P631, DOI 10.1038/bmt.2008.224eng
hcfmusp.relation.referenceDanylesko I, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0528-yeng
hcfmusp.relation.referenceDitschkowski M, 2009, BONE MARROW TRANSPL, V44, P265, DOI 10.1038/bmt.2009.8eng
hcfmusp.relation.referenceDumas PY, 2013, BONE MARROW TRANSPL, V48, P253, DOI 10.1038/bmt.2012.117eng
hcfmusp.relation.referenceEhrhardt MJ, 2016, BONE MARROW TRANSPL, V51, P83, DOI 10.1038/bmt.2015.203eng
hcfmusp.relation.referenceEngel N, 2019, LEUKEMIA, V33, P508, DOI 10.1038/s41375-018-0218-6eng
hcfmusp.relation.referenceBonong PRE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030288eng
hcfmusp.relation.referenceFlynn CM, 2007, BLOOD, V109, P2688, DOI 10.1182/blood-2006-07-021980eng
hcfmusp.relation.referenceFraser CJ, 2005, BLOOD, V106, P4377, DOI 10.1182/blood-2005-06-2551eng
hcfmusp.relation.referenceGallagher G, 2007, CANCER, V109, P84, DOI 10.1002/cncr.22375eng
hcfmusp.relation.referenceGilliland DG, 2002, BIOL BLOOD MARROW TR, V8, P9, DOI 10.1053/bbmt.2002.v8.pm11846355eng
hcfmusp.relation.referenceGong JZ, 2006, AM J SURG PATHOL, V30, P328eng
hcfmusp.relation.referenceGreaves MF, 2006, LEUKEMIA, V20, P1633, DOI 10.1038/sj.leu.2404293eng
hcfmusp.relation.referenceHertenstein B, 2005, HAEMATOLOGICA, V90, P969eng
hcfmusp.relation.referenceHou HA, 2009, BONE MARROW TRANSPL, V43, P315, DOI 10.1038/bmt.2008.325eng
hcfmusp.relation.referenceIcheva V, 2013, J CLIN ONCOL, V31, P39, DOI 10.1200/JCO.2011.39.8495eng
hcfmusp.relation.referenceInamoto Y, 2015, BONE MARROW TRANSPL, V50, P1013, DOI 10.1038/bmt.2015.63eng
hcfmusp.relation.referenceKnight JS, 2009, J CLIN ONCOL, V27, P3354, DOI 10.1200/JCO.2008.20.0857eng
hcfmusp.relation.referenceKonuma T, 2009, BONE MARROW TRANSPL, V43, P429, DOI 10.1038/bmt.2008.344eng
hcfmusp.relation.referenceLandgren O, 2009, BLOOD, V113, P4992, DOI 10.1182/blood-2008-09-178046eng
hcfmusp.relation.referenceLowe T, 2007, BIOL BLOOD MARROW TR, V13, P1121, DOI 10.1016/j.bbmt.2007.07.002eng
hcfmusp.relation.referenceMajhail NS, 2011, BRIT J HAEMATOL, V154, P301, DOI 10.1111/j.1365-2141.2011.08756.xeng
hcfmusp.relation.referenceMajhail NS, 2011, BLOOD, V117, P316, DOI 10.1182/blood-2010-07-294629eng
hcfmusp.relation.referenceMajhail Navneet S, 2008, Hematology Am Soc Hematol Educ Program, P142, DOI 10.1182/asheducation-2008.1.142eng
hcfmusp.relation.referenceMartin PJ, 2006, BIOL BLOOD MARROW TR, V12, P491, DOI 10.1016/j.bbmt.2006.03.004eng
hcfmusp.relation.referenceMatsunaga T, 2012, INT J HEMATOL, V96, P342, DOI 10.1007/s12185-012-1146-2eng
hcfmusp.relation.referenceOcheni S, 2008, BONE MARROW TRANSPL, V42, P181, DOI 10.1038/bmt.2008.150eng
hcfmusp.relation.referencePeric Z, 2012, BONE MARROW TRANSPL, V47, P251, DOI 10.1038/bmt.2011.64eng
hcfmusp.relation.referencePRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825eng
hcfmusp.relation.referenceRheingold S.R., 2003, HOLLAND FREI CANC ME, V6th ed.eng
hcfmusp.relation.referenceRicciardelli I, 2014, BLOOD, V124, P2514, DOI 10.1182/blood-2014-01-553362eng
hcfmusp.relation.referenceRingden O, 2014, BIOL BLOOD MARROW TR, V20, P1777, DOI 10.1016/j.bbmt.2014.07.009eng
hcfmusp.relation.referenceRizzo JD, 2009, BLOOD, V113, P1175, DOI 10.1182/blood-2008-05-158782eng
hcfmusp.relation.referenceRowlings PA, 1999, J CLIN ONCOL, V17, P3122, DOI 10.1200/JCO.1999.17.10.3122eng
hcfmusp.relation.referenceSala-Torra O, 2006, BIOL BLOOD MARROW TR, V12, P511, DOI 10.1016/j.bbmt.2006.01.006eng
hcfmusp.relation.referenceSanz J, 2014, BONE MARROW TRANSPL, V49, P397, DOI 10.1038/bmt.2013.190eng
hcfmusp.relation.referenceShimada K, 2005, BONE MARROW TRANSPL, V36, P115, DOI 10.1038/sj.bmt.1705020eng
hcfmusp.relation.referenceShimoni A, 2013, LEUKEMIA, V27, P829, DOI 10.1038/leu.2012.299eng
hcfmusp.relation.referenceShiozaki H, 2014, BONE MARROW TRANSPL, V49, P102, DOI 10.1038/bmt.2013.127eng
hcfmusp.relation.referenceSocie G, 2007, BLOOD, V109, P2794, DOI 10.1182/blood-2006-07-034272eng
hcfmusp.relation.referenceSpyridonidis A, 2020, BONE MARROW TRANSPL, V55, P1114, DOI 10.1038/s41409-020-0803-yeng
hcfmusp.relation.referenceStyczynski J, 2016, HAEMATOLOGICA, V101, P803, DOI 10.3324/haematol.2016.144428eng
hcfmusp.relation.referenceStyczynski J, 2013, CLIN INFECT DIS, V57, P794, DOI 10.1093/cid/cit391eng
hcfmusp.relation.referenceSyrjala KL, 2012, J CLIN ONCOL, V30, P3746, DOI 10.1200/JCO.2012.42.3038eng
hcfmusp.relation.referenceTakahashi S, 2007, BLOOD, V109, P1322, DOI 10.1182/blood-2006-04-020172eng
hcfmusp.relation.referenceTichelli A, 2019, JAMA ONCOL, V5, P229, DOI 10.1001/jamaoncol.2018.4934eng
hcfmusp.relation.referenceTichelli A, 2012, CURR PROBL DERMATOL, V43, P132, DOI 10.1159/000335271eng
hcfmusp.relation.referenceUhlin M, 2014, HAEMATOLOGICA, V99, P346, DOI 10.3324/haematol.2013.087338eng
hcfmusp.relation.referenceWiseman DH, 2011, BIOL BLOOD MARROW TR, V17, P771, DOI 10.1016/j.bbmt.2010.10.010eng
hcfmusp.relation.referenceYamasaki S, 2017, BONE MARROW TRANSPL, V52, P969, DOI 10.1038/bmt.2017.52eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationde2f3a4b-2ec5-4412-a066-2afdd291efc7
relation.isAuthorOfPublication.latestForDiscoveryde2f3a4b-2ec5-4412-a066-2afdd291efc7
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_RAFII_Outcomes_of_subsequent_neoplasms_after_umbilical_cord_blood_2023.PDF
Tamanho:
380.77 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03